MGIM
NBIX icon

M&G Investment Management’s Neurocrine Biosciences NBIX Stock Holding History

M&G Investment Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		$9.72M Buy
73,615
+5,781
+9% +$665K 0.03% 211
2023
Q3 		$7.67M Buy
67,834
+5,873
+9% +$618K 0.03% 225
2023
Q2 		$5.82M Buy
61,961
+1,928
+3% +$188K 0.02% 272
2023
Q1 		$6.06M Buy
+60,033
New +$6.25M 0.03% 231

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

M&G Investment Management's NBIX Position: Q4 2023 in Review

M&G Investment Management increased its Neurocrine Biosciences (NBIX) stake by 8.5% in Q4 2023, buying an estimated $665K and bringing the position to 73,615 shares worth $9.72M. The position accounts for 0.03% of the portfolio, ranked #211.

M&G Investment Management first reported a position in NBIX in Q1 2023 and has held it in 4 quarters since. 554 funds tracked by Wall St. Rank hold NBIX as of Q4 2023.

  • M&G Investment Management held 73,615 shares of Neurocrine Biosciences worth $9.72M as of Q4 2023.
  • M&G Investment Management bought 5,781 Neurocrine Biosciences shares in Q4 2023, an estimated $665K.
  • Neurocrine Biosciences made up 0.03% of M&G Investment Management's portfolio in Q4 2023, its #211 holding.
  • M&G Investment Management first reported a position in Neurocrine Biosciences in Q1 2023 and has held it in 4 quarters since.
  • 554 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2023.

Based on M&G Investment Management's 13F filing for Q4 2023, filed 8 Feb 2024.